Insufficient expression of factor VIII (fVIII) is a major hurdle in the development of successful nucleic acid treatments for hemophilia. However, we recently showed that under myeloablative and reduced-intensity total body irradiation (TBI) conditioning, transplantation of hematopoietic stem cells (HSCs) transduced with recombinant retroviruses containing B domain-deleted porcine (BDDp)fVIII sequences provides curative fVIII levels in a hemophilia A mouse model. In the current study, we test BDDpfVIII activity after nonmyeloablative conditioning with busulfan, cyclophosphamide or fludarabine and immunosuppressive agents CTLA4-Ig + anti-CD40L or anti-(murine)thymocyte serum (ATS). ATS is similar in action to anti-(human) thymocyte globulin (ATG), which is used clinically with busulfan in bone marrow transplantations to increase donor cell engraftment.
ABSTRACT
Insufficient expression of factor VIII (fVIII) is a major hurdle in the development of successful nucleic acid treatments for hemophilia. However, we recently showed that under myeloablative and reduced-intensity total body irradiation (TBI) conditioning, transplantation of hematopoietic stem cells (HSCs) transduced with recombinant retroviruses containing B domain-deleted porcine (BDDp)fVIII sequences provides curative fVIII levels in a hemophilia A mouse model. In the current study, we test BDDpfVIII activity after nonmyeloablative conditioning with busulfan, cyclophosphamide or fludarabine and immunosuppressive agents CTLA4-Ig + anti-CD40L or anti-(murine)thymocyte serum (ATS). ATS is similar in action to anti-(human) thymocyte globulin (ATG), which is used clinically with busulfan in bone marrow transplantations to increase donor cell engraftment.
Mice conditioned with busulfan + ATS and transplanted with BDDpfVIII-transduced stem cell antigen 1-positive cells exhibited moderate levels of donor cell chimerism (between 20 and 60%) and achieved sustained fVIII levels >1 U/mL. Similar results were observed in mice pre-immunized with human fVIII and conditioned with 5 Gy TBI + ATS or busulfan + ATS. These data demonstrate that it is possible to achieve sufficient fVIII expression after transplantation of BDDpfVIIItransduced HSCs following low-toxicity pre-transplantation conditioning with targeted immunosuppression, potentially even in the context of pre-existing inhibitors.
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INTRODUCTION
Hemophilia A is an X-linked recessive genetic disorder leading to a deficiency of functional clotting factor VIII (fVIII). One in 5,000 males is affected by hemophilia A, which in its severe form (accounting for approximately 50% of all cases) is life threatening. Clinically, the disease is characterized by spontaneous or traumatic bleeding, usually into joints or soft tissues but also into critical closed spaces such as the cranial cavity or retroperitoneal space. Spontaneous bleeds are most frequently observed in severe hemophiliacs, defined as those with < 0.01 U/mL fVIII activity.
Currently, the treatment of choice is prophylactic administration of recombinant fVIII protein with the goal of maintaining fVIII levels above 0.01 U/mL. Recombinant fVIII therapy for hemophilia A, while thought to be safer than plasma derived therapy, can be extremely costly with the average patient using up to $100,000 of fVIII product per year.
Therapy can also be complicated by infection or thrombosis of the central venous port typically required for repeated intravenous access in pediatric patients. In addition, up to 30% of severe hemophiliacs develop antibodies against fVIII, which often represents a neoantigen to their immune system, significantly increasing the complexity and cost of their care 1 .
In order to surmount the ongoing risk and cost of recombinant fVIII therapy, gene therapy has been proposed as a potential cure for hemophilia A. As a monogenic disorder requiring only modest improvements in circulating protein levels to afford significant clinical improvement, hemophilia A seems to be an ideal candidate for gene BDDpfVIII-modified HSCs into hemophilia A mice it is possible to achieve fVIII levels similar to that observed in normal mice and humans.
MATERIALS AND METHODS
This study was approved by Emory's IACUC.
Materials
DNA and RNA extraction kits were purchased from Qiagen (Valencia, CA). DNA extraction from peripheral blood was performed using the Puregene DNA purification system from Gentra (Minneapolis, MN). PCR reagents were purchased from Applied Biosystems (Foster City, CA). All antibodies for flow cytometry were purchased from BD Pharmingen (San Diego, CA). Recombinant cytokines were purchased from R&D Systems (Minneapolis, MN). COATEST SP fVIII assay kits were purchased from DiaPharma (West Chester, OH). Cell culture media and supplements were purchased from Invitrogen (Carlsbad, CA). Magnetic separation columns were purchased from 8, 9 . EGFP transgenic mice were used as donors in the HSC transplantation experiments. All transplanted mice were between eight to twelve weeks old. TBI was performed using a Gammacell 40 Exactor (Nordion, Ottawa, Ontario). Complete blood counts were performed on a Heska CBCDiff Veterinary Hematology System (Heska AG, Fribourg, Switzerland).
Production of MSCV-fVIII vectors and viral concentrates
MSCV-BDDpfVIII viral supernatant was produced as previously described /ml following concentration.
Isolation and transduction of murine stem cell antigen-1 + cells
Sca-1 + cell isolation was performed as previously described using positive immunomagnetic bead selection 3 . Prior to transduction, cells were stimulated for 2 days in serum-free media containing murine stem cell factor (100 ng/ml), murine interleukin-3 (20 ng/ml), human interleukin-11 (100 ng/ml) and human Flt-3 ligand (100 ng/ml). One million cells per well of a six well plate were transduced consecutively on days 3 and 4 with 1 -2 x 10 6 TU each day.
Transplantation of sca-1 + cells
Transduced cells were transplanted intravenously into conditioned recipient mice via tail vein injection on day 0. CY was administered intraperitoneally at 100 mg/kg/day on days -3 and -2 relative to transplantation. BU was given intraperiotneally either as 17. 
FVIII analyses
FVIII activity was measured using the activated partial thromboplastin one-stage coagulation assay and chromogenic fVIII activity assay as described previously 6 . Total anti-fVIII IgG levels were determined by enzyme-linked immunosorbant assay (ELISA)
as described previously 7, 8 . FVIII inhibitory activity was determined using a modified Bethesda assay 9 in which experimental plasma samples were incubated with human fVIII-deficient plasma reconstituted with recombinant BDD porcine fVIII for two hours and assayed for residual fVIII activity 8 . Intracellular staining for flow cytometry was performed using the Cytofix/Cytoperm kit according to the manufacturer's suggestions (BD Biosciences) with a biotinylated mouse anti-BDDpfVIII primary antibody.
Statistical Analysis
All values are expressed as mean ± sample standard deviation. Student's t-test was used for comparisons between groups unless otherwise noted.
RESULTS

Toxicities of nonmyeloablative and reduced-intensity regimens in hemophilia A mice
To translate genetically-modified HSCT to clinical applications for the treatment of hemophilia A, it is necessary to achieve sustained levels of fVIII following transplantation under conditioning regimens with an acceptable risk/benefit ratio. In the current study, we explored the myelo-and immunosuppressive properties of several clinically-relevant chemotherapeutic and immunosuppressive agents in a murine model of hemophilia A (Table 1) . We estimated that 10 -50% engraftment of donor cells would be necessary to allow for engraftment of sufficient genetically-modified cells, yet we anticipated the possibility of anti-BDDpfVIII inhibitory antibody formation under conditions that are less stringent than those previously demonstrated to be successful, i.e. 11 and 5.5 Gy TBI. Therefore, we also tested the effectiveness of co-administrating mild immunosuppression.
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From Complete blood counts (cbcs) were performed following each of the conditioning regimens listed in Table 1 While hemophilia A mice have a normal life expectancy with careful handling, we observed injection-associated toxicity following intraperitoneal administration of chemotherapeutic agents. In particular, the BU + CY treated mice showed elevated morbidity and mortality that was not observed in saline injected animals (Supplemental Figure 1 ). Based on necropsy findings of intraperitoneal hemorrhage and previously
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FVIII expression and inhibitor formation following BU + CY conditioning
Following transplantation of 3 x 10 5 sca-1 + cells, no engraftment was observed using BU + CY as conditioning agents, even though these regimens showed similar toxicity profiles as compared to 5.5 Gy and others have observed donor engraftment using higher cell doses 11 . Despite the observation that animals conditioned with BU or BU + CY had no detectable engraftment of donor cells, plasma fVIII activity was observed on day +7 post-transplantation, suggesting that transplanted progenitor and/or short-term repopulating cells are capable of fVIII production under these conditions. Mean fVIII activity levels were 0.05 ± 0.06 U/mL (5% of normal human fVIII levels) and 0.85 ± 0.68 U/mL (85% of normal human fVIII levels) on day 7 with BU and BU + CY conditioning, respectively. But, plasma fVIII activity was no longer detectable on and subsequent to day +14 post-transplantation ( Figure 2A ).
Having shown that these mice were exposed to BDDpfVIII produced from genetically- 
In vivo T cell depletion facilitates increased fVIII activity following HSCT gene therapy
Increased engraftment and fVIII activity following transplantation using costimulation blockade led us to explore further T-cell depletion regimens as part of the HSCT gene therapy protocol (Table 2) . Antithymocyte globulin (ATG) has been used widely in clinical bone marrow transplantation (BMT), to prevent and to treat graft-versus-host disease 14 . Additionally, ATG is increasingly being used as an adjuvant to nonmyeloablative conditioning regimens as a means of boosting donor cell engraftment.
We show that antithymocyte serum (ATS), which is a polyclonal rabbit-anti-mouse therapeutic fVIII activity levels of 3.14 ± 2.83 U/mL ( Figure 4B, 4C) . Therefore, ATS facilitated similar engraftment levels (p = 0.68) with higher fVIII activity (p = 0.00003) compared to costimulation blockade in BU conditioned mice ( Figure 3B and Figure 4B ).
We next sought to determine the lower limit of myelosuppression that would allow for sufficient engraftment of genetically-modified cells. Adding ATS to the low-dose BU (20 mg/kg) regimen increased engraftment of donor cells above 20 mg/kg BU alone (7.6% ± 9.6% versus 0%, respectively) but did not result in detectable plasma fVIII activity, except for one animal ( Figure 4B ). In order to determine if engraftment and fVIII activity We found a significant correction of clotting times in transplanted E16 -/-mice versus naïve E16 -/-mice (p<0.0001) as well as a significant correlation between BDDpfVIII activity levels by chromogenic assay and clot times in these mice (p<0.0001) (Supplemental Figure 2) . In order to determine if these mice would be tolerant to human fVIII in addition to BDDpfVIII, we administered 10 U of hfVIII 5 months posttransplantation. No anti-hfVIII or anti-BDDpfVIII ELISA titer was detected 1 week postchallenge and no significant change in BDDpfVIII levels was detected.
To determine which cells were responsible for fVIII production, 4 mice were sacrificed In primates, ATG eliminates peripheral blood T cells, while T cells within the lymphatic system are less affected at low ATG doses 16 . To determine if ATS acts similarly in hemophilia A mice, a cohort of animals was treated for 2 days with ATS and then blood, lymph nodes and spleen were collected on day +5. Similar to observations in nonhuman primate models, T cells were effectively cleared from the peripheral blood, but T cells in the spleen and in the peripheral lymphoid tissues were significantly less affected (p = 0.09 and 0.68, respectively) (Supplemental Figure 3) .
Sustained fVIII activity in pre-immunized mice facilitated by T-cell depletion
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From Given the success in naïve animals, we determined if sustained fVIII activity levels could be achieved in animals pre-immunized with hfVIII. We previously showed that lethally irradiated pre-immunized mice will engraft and express BDDpfVIII, but under reduced-intensity conditioning (5.5 Gy TBI) some animals failed to engraft with BDDpfVIII-transduced sca-1 + cells 6 . In the current study, hemophilia A mice were injected intravenously once every week with recombinant hfVIII for 6 weeks. In this study, we found that BU + ATS conditioning and HSCT gene therapy promoted sustained, supraphysiological levels of fVIII. While 12 mg/kg BU is considered to be the limit of nonmyeloablative conditioning in humans, 20 -35 mg/kg was needed in mice to achieve the same level of engraftment that would be anticipated with 8 -12 mg/kg BU in humans.
As shown, the levels of BU used in this study were minimally myelosuppressive with very little effect observed in peripheral blood counts. Lower than expected donor cell engraftment may occur since transplantation of eGFP + C57BL/6
genetically-modified donor cells into C57BL/6 hemophilia A mice does not truly replicate the scenario of autologous HSCT, as the expression of both eGFP and fVIII are immunogenic. This factor combined with the 4-day transduction protocol and the transplantation of low sca-1 + cell numbers in the current study can account for the decreased engraftment observed under some reduced-intensity conditioning regimens.
Malignant transformation due to insertional mutagenesis has been proven to be a potential adverse event associated with MSCV-based retroviral gene transfer 23, 24 .
Therefore, another consideration for successfully translating genetically-modified HSCT for the treatment of hemophilia A is the necessity of producing sufficient fVIII under conditions of limited proviral insertion per genetically-modified cell. In order to decrease the risk of insertional mutagenesis, both the moi and number of genetically-modified
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Compared to the transplantation of >10 6 bone marrow cells into a single animal, this experimental design also more accurately reproduces a scenario of autologous transplantation in which the number of stem cells (e.g. CD34 + cells) that can be collected from an individual patient prior to selection, transduction and transplantation is limiting 18 . As another safety measure, a platelet-specific promoter was recently used for fVIII gene therapy and was shown to be feasible in a mouse model of hemophilia A 19, 20 .
Our observation that the majority of BDDpfVIII-positive cells in the bone marrow 12
weeks post-transplantation were granulocytes may lend some additional insight into the ability of certain lingeages of hematopoietic cells to efficiently express this transgene 21 .
However, as shown by Klug et al 22 , the apparent selective expression in granulocytes may be due to LTR inactivation in the T cell population. So, while further studies are needed to explore the relationship between intracellular staining and fVIII secretion by these cells, the knowledge that a specific cell type efficiently expresses fVIII could lead to a safer retroviral vector using a lineage-specific promoter.
Clinical trials have shown the difficulty of achieving sufficient fVIII expression using several gene transfer strategies, partially because fVIII is an inefficiently produced protein. In addition, Hawley and colleagues observed only modest fVIII levels in mice after transplantation of bone marrow cells genetically modified with a L303E/F309S fVIII double mutant 28 . This mutant was previously shown to increase fVIII expression due to enhanced fVIII secretion, which presumably results from more efficient trafficking from
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From the endoplasmic reticulum to the Golgi. We previously showed that BDDpfVIII overcomes the low expression barrier and >100% normal human fVIII levels were achieved after transplant of BDDpfVIII-modified sca-1 + cells under myeloablative and reduced intensity TBI-based conditioning regimens 3 . In the current study using primarily non-TBI-based reduced intensity conditioning regimens, we again show that the BDDpfVIII construct overcomes the low expression barrier and demonstrate sustained curative fVIII levels in recipient animals. Further studies are required to determine if similar expression levels can be achieve from human hematopoietic cells and, therefore, testing human CD34 + cells both in vitro and in NOD/SCID mouse models is warranted.
In the majority of mice we observed maximum fVIII activity within the first month after transplant ( Figures 4B, 4F, 6D, 6F ). During this period, fVIII expression is likely derived from integrated and non-integrated transgene containing cells and from geneticallymodified lineage-committed progenitor cells, short-term repopulating cells and HSCs. It would be predicted that this would lead to a burst of fVIII activity following transplantation, followed by fluctuations during the initial weeks post-transplantation as different cell populations expand and then become extinct, thereby altering the plasma fVIII levels, which was observed. In the absence of immunosuppression, as observed in the BU or BU + CY groups, the exposure to BDDpfVIII likely led to immune activation, inhibitory antibody formation, and rejection of genetically-modified cells. However, we
showed that with the incorporation of additional immunosuppression into the conditioning protocol (i.e. costimulation blockade or ATS) the recipient animals became
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From nonresponsive to the BDDpfVIII transgene product and were able to sustain high levels of fVIII activity without anti-BDDpfVIII immune activation. Additionally, these mice were nonresponsive to hfVIII when challenged 5 months post-transplantation. The observation that T cells are not depleted from lymph nodes and are only mildly decreased in spleen is consistent with human studies but still perplexing as to the mechanism of tolerance induction in the current study. Our ongoing studies designed to determine the mechanisms of tolerance induction in this model should provide further insight into the mechanism of fVIII immunogenicity. Because no anti-fVIII immune response was observed, it is possible that the mechanism of tolerance in our model is distinct from the mechanism involved in fVIII immune tolerance induction therapy in which large doses of hfVIII are administered in an effort to exhaust the patient's fVIIIspecific immune response 23 . In addition, because costimulation blockade has little effect on T cell numbers, it is possible that tolerance through the use of ATS and costimulation blockade are through different mechanisms. These data suggest that multiple routes of immune tolerance induction may be possible in the clinical use of gene-modified HSCT.
Patients with inhibitory antibodies against fVIII are extremely difficult and costly to manage, and represent the patient population that could most benefit from a novel therapeutic alternative. Our previous studies in pre-immunized mice 6 indicated that with sufficient myeloablation, engraftment of BDDpfVIII-transduced HSCs could be achieved, and no further inhibitor antibody development was observed. These results were somewhat expected based on previous studies on the effects of TBI on the B cell 24 . In the current study, we show that reduced-intensity conditioning with BU + ATS is sometimes successful when applied to mice with pre-existing immunity to hfVIII and that these mice were nonresponsive to both BDDpfVIII and hfVIII. We, therefore, conclude that the goal of nonmyeloablative conditioning and HSCT gene therapy is feasible in this patient population, but more aggressive pre-conditioning may be required for engraftment of genetically-modified cells and sustained expression of fVIII in the pre-sensitized setting.
The goal of the current study was to determine if HSCT incorporating BDDpfVIII gene- Mice were assayed biweekly after day +14 and no fVIII activity was detected in any mice. (B) Anti-BDDpfVIII inhibitory antibody titers as determined by the Bethesda assay.
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